Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature

Delgado-Fernández, Marcial; García-Gemar, Gracia Mar; Fuentes-López, Ana; Muñoz-Pérez, Manuel Isidro; Oyonarte-Gómez, Salvador; Ruíz-García, Ignacio; Martín-Carmona, Jessica; Sanz-Cánovas, Jaime; Castaño-Carracedo, Manuel Ángel; Reguera-Iglesias, José María; Ruiz-Mesa, Juan D.

doi:10.1016/j.eimce.2021.01.009

Cited by 6 publications

(4 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, in a case-control study, Thompson et al observed a reduced overall mortality in patients with hematological malignancies treated with ConvP [8]. Our findings are also in line with other smaller case series [9,10]. Taken together, B-cell-depleted patients with COVID-19 without serological evidence of an autologous anti-SARS-CoV-2 antibody response seem to be a distinct subpopulation where ConvP therapy has a potential benefit, and this benefit may be present regardless of symptom duration.…”

Section: Discussionsupporting

confidence: 92%

“…Temporary worsening of hypoxemia might be related to binding of virusneutralizing antibodies to virus particles and the resulting antibody-dependent enhancement of the inflammatory response in the lungs. Antibody-naive individuals might be more at risk for this phenomenon of antibody-dependent enhancement, also reported by others [10]. However, in the majority of patients there was no increase in the inflammatory marker CRP after infusion of ConvP, as might have been expected when immune complexes would have activated macrophages to produce interleukin 6 [11].…”

Section: Discussionsupporting

confidence: 60%

See 1 more Smart Citation

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients

Gharbharan

GeurtsvanKessel

Jordans

et al. 2021

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 60%

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients

Gharbharan

GeurtsvanKessel

Jordans

et al. 2021

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

“… 87 , 112 According to 2 controlled studies in this cohort, 119 , 120 CCP treatment was shown to be related to considerably increased survival rates, while an uncontrolled case series revealed that CCP infusions resulted in clinical benefits. 121 , 122 In Accordance with a preliminary study, immune-compromised patients with COVID-19 in an early stage of sickness and no detectable anti-SARS-CoV-2 antibodies are potential candidates for CCP treatment, and patients with a high post-transfusion antibody titer have the highest chance of success. 123 …”

Section: Discussionmentioning

confidence: 79%

“… The lack of adverse events due to transfusions and the low MR (3.3%) in this trial demonstrated the efficacy of CPT. Marcial Delgado-Fernández et al From Spanish 121 An analysis of the literature and 3 consecutive cases of COVID-19 Tx with CP in patients with HIDs (Review) March to mid-June 2021 3 patients Administration of CP in doses from 200 to 800 mL. Following transfusion, abs levels were either low or negative, indicating that they may have been used to neutralize SARS-CoV-2.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Kandula¹,

Tuji²,

Gudeta³

et al. 2023

JBM

View full text Add to dashboard Cite

Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.

show abstract

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

et al. 2023

View full text Add to dashboard Cite

ImportancePatients who are immunocompromised have increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19) because they less frequently mount antibody responses to vaccines. Although neutralizing anti-spike monoclonal-antibody treatment has been widely used to treat COVID-19, evolutions of SARS-CoV-2 have been associated with monoclonal antibody-resistant SARS-CoV-2 variants and greater virulence and transmissibility of SARS-CoV-2. Thus, the therapeutic use of COVID-19 convalescent plasma has increased on the presumption that such plasma contains potentially therapeutic antibodies to SARS-CoV-2 that can be passively transferred to the plasma recipient.ObjectiveTo assess the growing number of reports of clinical experiences of patients with COVID-19 who are immunocompromised and treated with specific neutralizing antibodies via COVID-19 convalescent plasma transfusion.Data SourcesOn August 12, 2022, a systematic search was performed for clinical studies of COVID-19 convalescent plasma use in patients who are immunocompromised.Study SelectionRandomized clinical trials, matched cohort studies, and case report or series on COVID-19 convalescent plasma use in patients who are immunocompromised were included. The electronic search yielded 462 unique records, of which 199 were considered for full-text screening.Data Extraction and SynthesisThe study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data were extracted by 3 independent reviewers in duplicate and pooled.Main Outcomes and MeauresThe prespecified end point was all-cause mortality after COVID-19 convalescent plasma transfusion; exploratory subgroup analyses were performed based on putative factors associated with the potential mortality benefit of convalescent plasma.ResultsThis systematic review and meta-analysis included 3 randomized clinical trials enrolling 1487 participants and 5 controlled studies. Additionally, 125 case series or reports enrolling 265 participants and 13 uncontrolled large case series enrolling 358 participants were included. Separate meta-analyses, using models both stratified and pooled by study type (ie, randomized clinical trials and matched cohort studies), demonstrated that transfusion of COVID-19 convalescent plasma was associated with a decrease in mortality compared with the control cohort for the amalgam of both randomized clinical trials and matched cohort studies (risk ratio [RR], 0.63 [95% CI, 0.50-0.79]).Conclusions and RelevanceThese findings suggest that transfusion of COVID-19 convalescent plasma is associated with mortality benefit for patients who are immunocompromised and have COVID-19.

show abstract

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature

Cited by 6 publications

References 68 publications

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About